Our products are unique and technologically advanced. MEDIVIS was the first company in the world to discover the potential of hyaluronic acid for the treatment of dry-eye as well as delivery system for active principles of eye medications.

Medivis is the first ophthalmic company able to stabilize iodine (at very low concentration as iodide povidone) in an aqueous nanoemulsion. IODIM is the most powerful and best tolerated ocular antiseptics as topical ophthalmic product.

We have also been pioneers in applying biotherapy using the enormous potential of endopharmacology. We have, in fact, developed a product based on two natural substances already present in the human body, included the eye, such as cortisol and hyaluronic acid, creating the golden therpay of inflammation due to dry eye and Sjogren syndrome, two of the most widespread eye patholgies.

Our constant attention to research has allowed us to achieve another exciting result: improving the intraocular bioavailability of drugs by developing a nanotechnological platform (worldwide patented) usefull to solubilize and deliver hydrophilic and lipophilic active ingredients for the topical treatment of eye diseases.

During 2022, Medivis granted an exclusive license to use its IP to one of the largest Italian pharmaceutical companies, DOC Generici, which markets products, throughout Italy. Medivis will continue to market its portfolio in the rest of the world.